Source comparison
MK-677 Cycling: Comparison of Dosing Protocols
Continuous (Daily) 15–25mg every 24 hours indefinitely Yes. Sustained for 12+ months in trials None observed in published data None. Ghrelin pathway doesn't suppress endogenous GH Long-term anabolic research, body recomposition studies, extended metabolic obse
This comparison does not assign a generated winner or score.
- Continuous (Daily)
- 15–25mg every 24 hours indefinitely
- Yes. Sustained for 12+ months in trials
- None observed in published data
- None. Ghrelin pathway doesn't suppress endogenous GH
- Long-term anabolic research, body recomposition studies, extended metabolic observation
- Optimal for sustained IGF-1 signaling. No physiological reason to interrupt dosing unless monitoring glucose dysregulation
- Traditional Cycling (8 weeks on / 4 weeks off)
- 15–25mg daily for 8 weeks, then stop for 4 weeks
- No. IGF-1 returns to baseline within 72 hours of cessation
- None. Ghrelin receptors remain responsive during off-period
- None. No rebound suppression during off-cycle
- Researchers unfamiliar with ghrelin agonist kinetics, protocols designed around SARM frameworks
- Wastes 33% of timeline rebuilding IGF-1 levels already achieved. Not evidence-based for MK-677
- Intermittent Dosing (5 days on / 2 days off)
- 15–25mg daily Mon–Fri, skip weekends
- Partial. Weekend cessation causes minor IGF-1 decline
- None
- Cost reduction strategies, convenience-driven protocols
- Suboptimal. Introduces unnecessary variability in serum levels without any receptor or hormonal benefit
- Pulsed High-Dose (3x per week)
- 40–50mg three times weekly (e.g., Mon/Wed/Fri)
- No. Unstable plasma concentrations, frequent troughs
- Misapplication of peptide pulsing principles
- Not supported by MK-677 pharmacokinetics. 24-hour half-life requires daily dosing for stable levels